VE‐cadherin‐CreERT2 transgenic mouse: A model for inducible recombination in the endothelium

A Monvoisin, JA Alva, JJ Hofmann… - … dynamics: an official …, 2006 - Wiley Online Library
A Monvoisin, JA Alva, JJ Hofmann, AC Zovein, TF Lane, ML Iruela‐Arispe
Developmental dynamics: an official publication of the American …, 2006Wiley Online Library
To introduce temporal control in genetic experiments targeting the endothelium, we
established a mouse line expressing tamoxifen‐inducible Cre‐recombinase (Cre‐ERT2)
under the regulation of the vascular endothelial cadherin promoter (VECad). Specificity and
efficiency of Cre activity was documented by crossing VECad‐Cre‐ERT2 with the ROSA26R
reporter mouse, in which a floxed‐stop cassette has been placed upstream of the β‐
galactosidase gene. We found that tamoxifen specifically induced widespread …
Abstract
To introduce temporal control in genetic experiments targeting the endothelium, we established a mouse line expressing tamoxifen‐inducible Cre‐recombinase (Cre‐ERT2) under the regulation of the vascular endothelial cadherin promoter (VECad). Specificity and efficiency of Cre activity was documented by crossing VECad‐Cre‐ERT2 with the ROSA26R reporter mouse, in which a floxed‐stop cassette has been placed upstream of the β‐galactosidase gene. We found that tamoxifen specifically induced widespread recombination in the endothelium of embryonic, neonatal, and adult tissues. Recombination was also documented in tumor‐associated vascular beds and in postnatal angiogenesis assays. Furthermore, injection of tamoxifen in adult animals resulted in negligible excision (lower than 0.4%) in the hematopoietic lineage. The VECad‐Cre‐ERT2 mouse is likely to be a valuable tool to study the function of genes involved in vascular development, homeostasis, and in complex processes involving neoangiogenesis, such as tumor growth. Developmental Dynamics 235:3413–3422, 2006. © 2006 Wiley‐Liss, Inc.
Wiley Online Library